Investment
Features
FeesSafety
Academy
More
Pluang+

Invesco S&P Ultra Dividend Revenue ETF rated Hold due to fair yield but limited growth prospects.

Analyst Insights
29 Sep 2026
Seeking Alpha
View Source
Neutral
Invesco S&P Ultra Dividend Revenue ETF rated Hold due to fair yield but limited growth prospects.

The Invesco S&P Ultra Dividend Revenue ETF (RDIV) holds a rating of Hold because its yield of about 3.65% is fairly valued and supported by durable income and recent dividend growth. However, the ETF's heavy exposure to bond-like sectors such as utilities, REITs, and staples limits its upside potential, especially in a high interest rate environment. The expected returns are mid-single-digit, mostly from yield, which offers limited compensation for the equity risk compared to safer Treasury investments. This makes RDIV less attractive for investors seeking strong growth or outperformance catalysts.

The Invesco S&P Ultra Dividend Revenue ETF (RDIV) is presented here with Pluang's market data for context. For readers following US stocks, the breadth was 45 gainers and 105 losers out of 150 priced stocks. Notable movers included TME at USD 7.95 with a 5.02% decline, NIO at USD 3.41 down 5.01%, and LI at USD 11.12 down 5.00%, as of Sep 29, 2026 23:02 WIB.

More News

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron Technology is set to report record quarterly revenue of up to $51.33 billion, fueled by strong demand for high-bandwidth memory in the AI market. Earnings per share are expected to jump significantly to around $31.72, compared to $3.03 last ye...

Company Fundamentals
Bullish
21 minutes ago
Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma Technologies reported a smaller-than-expected loss with an EPS of -$0.08, beating analyst estimates of -$2.19, though its revenue of $48.55 million slightly missed expectations. Despite ongoing profitability challenges reflected in a negative...

Company Fundamentals
Bullish
2 hours ago
Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics has increased its full-year 2026 revenue guidance to $410-$420 million, reflecting nearly 60% growth driven by strong U.S. demand for its cancer therapy Amtagvi, which generated $91 million in Q2 sales. Analyst Joseph Pantgini...

Analyst Insights
Bullish
3 hours ago
uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure's stock fell sharply by 37% following a four-year update on its AMT-130 gene therapy for Huntington's disease, which showed reduced effectiveness from 80% at three years to 44% at four years, failing to reach statistical significance. Despite...

Market News
Bearish
3 hours ago
Silver Elephant Mining ups private placement to raise CAD 882K for working capital.

Silver Elephant Mining ups private placement to raise CAD 882K for working capital.

Silver Elephant Mining Corp. has increased its non-brokered private placement to 7.35 million units at CAD 0.12 each, aiming to raise up to CAD 882,000. Each unit includes one common share and one warrant to buy an additional share at CAD 0.16 within...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App